Halozyme Therapeutics (HALO) announced that Johnson & Johnson (JNJ) received U.S. FDA approval of a new indication for DARZALEX Faspro co-formulated with ENHANZE, as single agent treatment of adult patients with high-risk smoldering multiple myeloma. DARZALEX Faspro is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multiple myeloma.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Announces Pricing of $1.3 Billion in Notes
- Halozyme Extends Credit Facility and Increases Commitments
- Halozyme announces two offerings totalling $1.3B in convertible senior notes
- Halozyme Therapeutics’ Earnings Call Highlights Robust Growth
- Halozyme price target raised to $92 from $91 at Citizens JMP